Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
Legend Biotech (NASDAQ: LEGN) has announced it will host an investor conference call on Tuesday, November 12, 2024, at 8:00 am ET to discuss third-quarter 2024 financial results. Senior leadership will present the company's quarterly performance during the call. Investors can access the live audio webcast through a provided weblink, with a replay and earnings release available on the company's Investor Relations website approximately two hours after the call.
Legend Biotech (NASDAQ: LEGN) ha annunciato che ospiterà una conferenza telefonica per gli investitori il martedì 12 novembre 2024, alle 8:00 ET per discutere i risultati finanziari del terzo trimestre 2024. I membri della direzione senior presenteranno le performance trimestrali dell'azienda durante la chiamata. Gli investitori possono accedere alla diretta audio tramite un link fornito, con una registrazione e un comunicato sugli utili disponibili sul sito web delle Relazioni con gli Investitori dell'azienda circa due ore dopo la chiamata.
Legend Biotech (NASDAQ: LEGN) ha anunciado que organizará una conferencia telefónica para inversores el martes 12 de noviembre de 2024, a las 8:00 am ET para discutir los resultados financieros del tercer trimestre de 2024. La alta dirección presentará el rendimiento trimestral de la empresa durante la llamada. Los inversores pueden acceder a la transmisión de audio en vivo a través de un enlace proporcionado, y una repetición y el comunicado de ganancias estarán disponibles en el sitio web de Relaciones con Inversores de la empresa aproximadamente dos horas después de la llamada.
레전드 바이오텍 (NASDAQ: LEGN)은 2024년 11월 12일 화요일 오전 8:00 ET에 투자자 회의 전화를 개최하여 2024년 3분기 재무 결과를 논의할 것이라고 발표했습니다. 고위 경영진이 전화 회의 중 회사의 분기 실적을 발표할 예정입니다. 투자자들은 제공된 웹 링크를 통해 실시간 오디오 웹캐스트에 접속할 수 있으며, 회의 종료 약 2시간 후 회사의 투자자 관계 웹사이트에서 다시보기와 실적 발표를 확인하실 수 있습니다.
Legend Biotech (NASDAQ: LEGN) a annoncé qu'elle tiendra une conférence téléphonique pour les investisseurs le mardi 12 novembre 2024, à 8h00 ET pour discuter des résultats financiers du troisième trimestre 2024. La direction présentera les résultats trimestriels de l'entreprise lors de cet appel. Les investisseurs peuvent accéder à la diffusion audio en direct via un lien fourni, et une rediffusion ainsi qu'un communiqué de résultats seront disponibles sur le site Web des Relations avec les investisseurs de l'entreprise environ deux heures après l'appel.
Legend Biotech (NASDAQ: LEGN) hat angekündigt, dass am Dienstag, den 12. November 2024, um 8:00 Uhr ET eine Telefonkonferenz für Investoren stattfinden wird, um die finanziellen Ergebnisse des dritten Quartals 2024 zu besprechen. Die obere Führungsebene wird während der Konferenz die Quartalsleistung des Unternehmens präsentieren. Investoren können über einen bereitgestellten Weblink auf das Live-Audio-Stream zugreifen, und eine Wiederholung sowie die Gewinnbekanntgabe werden ungefähr zwei Stunden nach dem Anruf auf der Website für Investor Relations des Unternehmens verfügbar sein.
- None.
- None.
SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, November 12, 2024, to review third-quarter 2024 results.
During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter.
Investors and other interested parties may join the live audio webcast of the call via this weblink.
A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech’s website under the Events and Presentation section approximately two hours after the call concludes.
ABOUT LEGEND BIOTECH
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell (gd T) and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Mary Ann Ondish
Tel: (914) 552-4625
media@legendbiotech.com
FAQ
When is Legend Biotech (LEGN) reporting Q3 2024 earnings?
How can I access Legend Biotech's (LEGN) Q3 2024 earnings call?
What will be discussed in Legend Biotech's (LEGN) Q3 2024 earnings call?
